Sunday, 5 May 2013

Global Pain Management Market-Research Report

Pain Management Outlook-Market Research Report-Competitive Landscape


Dissertation Writing on Global Pain Management

Market Research Report on Global Pain Management-Major Players

Sales of the top 10 companies in the global pain management market totaled $26.5bn in 2007, an increase of 16.2% y-o-y. The growth of the leading companies in the pain segment outperformed that of the overall market, which registered a growth of 12.5% y-o-y during 2007.

  • Pfizer was the leading player in the pain management market in 2007, with sales of $5.5bn, an increase of 14.6% y-o-y. Celebrex registered sales of $2.3bn,followed by Lyrica with $1.9bn. Together these brands accounted for 75.5% of the overall sales accrued by Pfizer that year. The company remained the market leader in the global anticonvulsant and coxibs segment during 2007.
  • J&J retained second position in the global pain management market in 2007, with sales of $4.8bn, an increase of 10.1% on the previous year's sales. Topamax led the sales of J&J’s pain management portfolio with a 52.1% share, amounting to$2.5bn. Despite declining sales, Duragesic continues to propel J&J towards becoming the market leader in the non-narcotic analgesics segment.
  •  Novartis was the third largest player in the pain management market in 2007 with sales of $3.3bn, an increase of 8.7% on the back of continued growth of Trileptal and Voltaren. Trileptal registered $836m sales, while Voltaren registered $638m,growing moderately. Voltaren remains the key growth driver in the antirheumatic NSAIDs segment.
  •  Mundipharma ranked fifth in the global pain management market with $2bn salesin 2007. It continued to maintain the leadership position in the narcotic analgesics segment, driven by the recent settlement with generic players to halt any further marketing of generic oxycodone.
 Global market analysis

  •  The global pain management market was valued at $46.4bn in 2007, an increase of12.5% y-o-y.
  •  Analgesics, comprising narcotics and non-narcotics, generated sales of $19.9bn during 2007 and thus captured 43.0% of the global pain management market, while demonstrating robust growth of 15.2% y-o-y. The narcotics segment is led by Mundipharma’s OxyContin CR, while the highly fragmented non-narcotic segment is led by BMS’s Efferalgan and J&J’s Tylenol.
  •  Although anticonvulsant brands demonstrated the strongest growth during 2007,sales originated primarily from prescriptions for the management of seizure disorders rather than pain. Analysis of the prescription trends in the seven major markets revealed that only 7.8% of prescriptions of anticonvulsant products were intended for pain management.
  •  NSAIDs formed the third largest segment of the global pain management market,with $9.3bn in sales accrued during 2007. This class was primarily driven by antirheumatic NSAIDs. Celecoxib, the only coxib currently approved in the US market,dominates this segment of the drug class.
  •  Local anesthetics constituted the smallest segment of the global pain management market with 4.2% of the market, or $1.9bn in sales, during 2007. The segment was driven by the strong growth of Endo’s Lidoderm, which captured a significant45.4% share.
  •  The global pain management market is forecast to rise at a CAGR of 3.1% over 2007–14 to reach $57.2bn by 2014. This is likely to be fueled by the continued growth of the analgesics segment, the market share of which is expected to increase to 47.0% in 2014.
If you want Market Research Reports on Pain Management, contact us at +91 9819650213 or mail